S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
NASDAQ:BMEA

Biomea Fusion (BMEA) Competitors

$12.89
+0.18 (+1.42%)
(As of 10/3/2023 ET)
Compare
Today's Range
$12.32
$13.19
50-Day Range
$12.71
$22.25
52-Week Range
$6.04
$43.69
Volume
360,413 shs
Average Volume
672,629 shs
Market Capitalization
$459.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.88

BMEA vs. SVRA, TRDA, HROW, EOLS, ANAB, WVE, RPTX, RNA, PAHC, and TBPH

Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Savara (SVRA), Entrada Therapeutics (TRDA), Harrow Health (HROW), Evolus (EOLS), AnaptysBio (ANAB), Wave Life Sciences (WVE), Repare Therapeutics (RPTX), Avidity Biosciences (RNA), Phibro Animal Health (PAHC), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical preparations" industry.

Biomea Fusion vs.

Biomea Fusion (NASDAQ:BMEA) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation.

Savara has higher revenue and earnings than Biomea Fusion. Savara is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomea FusionN/AN/A-$81.83M-$3.32-3.88
Savara$260K1,881.98-$38.15M-$0.28-12.93

Savara received 254 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 65.34% of users gave Savara an outperform vote while only 55.56% of users gave Biomea Fusion an outperform vote.

CompanyUnderperformOutperform
Biomea FusionOutperform Votes
25
55.56%
Underperform Votes
20
44.44%
SavaraOutperform Votes
279
65.34%
Underperform Votes
148
34.66%

In the previous week, Biomea Fusion and Biomea Fusion both had 2 articles in the media. Savara's average media sentiment score of 1.00 beat Biomea Fusion's score of 0.89 indicating that Savara is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biomea Fusion
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Savara
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

93.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 97.3% of Savara shares are owned by institutional investors. 26.3% of Biomea Fusion shares are owned by insiders. Comparatively, 4.6% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Savara's return on equity of -41.62% beat Biomea Fusion's return on equity.

Company Net Margins Return on Equity Return on Assets
Biomea FusionN/A -74.75% -64.28%
Savara N/A -41.62%-31.81%

Biomea Fusion presently has a consensus price target of $43.88, suggesting a potential upside of 240.38%. Savara has a consensus price target of $5.00, suggesting a potential upside of 38.12%. Given Biomea Fusion's higher probable upside, equities analysts clearly believe Biomea Fusion is more favorable than Savara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomea Fusion
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89
Savara
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Biomea Fusion has a beta of -1.05, indicating that its stock price is 205% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Summary

Savara beats Biomea Fusion on 11 of the 15 factors compared between the two stocks.


Get Biomea Fusion News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMEA vs. The Competition

MetricBiomea FusionPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$459.27M$6.08B$4.44B$6.22B
Dividend YieldN/A2.73%5.94%7.83%
P/E Ratio-3.887.42128.3113.38
Price / SalesN/A179.932,899.9768.08
Price / CashN/A19.0421.5022.77
Price / Book3.494.003.814.57
Net Income-$81.83M$203.39M$121.52M$181.79M
7 Day Performance-7.20%-2.56%-2.15%-2.11%
1 Month Performance-24.75%-11.63%-8.16%-9.22%
1 Year Performance27.25%2.29%4.71%-0.98%

Biomea Fusion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SVRA
Savara
2.13 of 5 stars
$3.70
-1.1%
$5.00
+35.1%
+135.1%$500.13M$260,000.00-13.21N/APositive News
TRDA
Entrada Therapeutics
1.6895 of 5 stars
$14.88
-0.3%
$21.50
+44.5%
-4.4%$494.02MN/A-5.77131Positive News
HROW
Harrow Health
2.1494 of 5 stars
$14.03
-5.2%
$38.80
+176.6%
+5.1%$492.73M$88.60M-25.05182Short Interest ↑
EOLS
Evolus
2.148 of 5 stars
$8.87
-1.3%
$21.40
+141.3%
+3.3%$505.32M$148.62M-7.58215Short Interest ↑
ANAB
AnaptysBio
1.6451 of 5 stars
$18.15
+4.7%
$34.75
+91.5%
-28.8%$481.88M$10.29M-3.5096Positive News
WVE
Wave Life Sciences
1.9098 of 5 stars
$5.29
-0.4%
$7.00
+32.3%
+65.0%$523.60M$3.65M-3.89250
RPTX
Repare Therapeutics
1.919 of 5 stars
$12.45
-2.0%
$21.00
+68.7%
-10.4%$524.02M$131.83M-83.00180
RNA
Avidity Biosciences
1.7174 of 5 stars
$6.38
+1.3%
$38.17
+498.2%
-60.0%$472.76M$9.22M-2.06186Positive News
PAHC
Phibro Animal Health
2.7496 of 5 stars
$13.01
-1.6%
$18.67
+43.5%
-8.0%$526.91M$977.90M16.061,920
TBPH
Theravance Biopharma
2.2862 of 5 stars
$8.90
-5.0%
$17.00
+91.0%
-14.5%$470.01M$51.35M0.78359Positive News

Related Companies and Tools

This page (NASDAQ:BMEA) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -